Sustained control of hypertension reduces the morbidity and mortality of cardiovascular disease.1,2 A key message from the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guidelines is that in persons 60 years or older, systolic hypertension is a more important risk factor for cardiovascular disease than diastolic hypertension.2 It is the component of blood pressure (BP) most likely to be "uncontrolled" in population studies.3 Systolic hypertension is defined as systolic blood pressure (SBP) of 140 mm Hg or higher and diastolic BP of less than 90 mm Hg.
The latest data from the National Health and Nutrition Examination Survey (NHANES) indicate that more than 50 million Americans have hypertension.4 Although awareness and control of hypertension have improved during the past 2 decades, about 30% of hypertensive Americans are unaware that they have hypertension, 40% are not receiving therapy, and 66% or more who are being treated have suboptimal control. Elderly patients are the ones most likely to have inadequately controlled BP (usually SBP).5 In this article, we review the pathophysiology of systolic hypertension as well as the most current treatment approaches.
The causes of essential hypertension include genetic factors, increased sympathetic nervous system activity, a variety of circulating humors, and vascular remodeling. Evidence for the role of genetic factors comes from the finding of a clustering of this condition in families.6 In addition, there is BP concordance among monozygotic twins and biological siblings compared with adopted siblings raised together.7,8 A few hypertensive disorders result from single gene mutations (eg, Liddle syndrome), but most cases of essential hypertension probably result from mutations of multiple genes in addition to environmental factors. Notably, persons with hypertension also tend to inherit diabetes and lipid disorders.9 Data from studies in families using ambulatory BP monitoring suggest that both systolic and diastolic hypertension patterns are inherited.10
Hypertension is often characterized by increased sympathetic nervous system activity. Evidence that an elevated heart rate correlates with the development of hypertension corroborates this finding.11 Increased sympathetic tone leads to elevated diastolic pressure, vascular remodeling, and likely end-organ damage, particularly left ventricular hypertrophy (LVH). Humoral factors, such as norepinephrine, angiotensin II, transforming growth factor b, and insulin-like growth factor, are implicated in the enhanced activation of the sympathetic nervous system. There is also evidence of increased sympathetic activity in the kidneys in hypertension.9
The vascular remodeling that occurs in hypertension leads to increased peripheral vascular resistance and increased pulse wave velocity. The arterial bed stores substrate-enriched blood and acts as a conduit for its delivery to systemic organs and tissues. Arterial mechanics depend on arterial stiffness, arterial wall thickness, and arterial diameter. Arterial stiffness is a measurable and important cardiovascular risk factor. Arteries stiffen as a consequence of the increased collagen deposition, fragmentation, and loss of elastin that occur with aging. This manifests clinically as elevated pulse wave velocity (PWV), the speed at which the pulse wave travels through the arterial bed.
In young persons, large, healthy arteries such as the aorta have low PWV values. This slower PWV enables the pulse wave to reflect back to the aorta in a timely manner to reduce the pressure load to the smaller peripheral arteries and at the same time reach the central circulation at an appropriate time in the cardiac cycle so as to augment coronary blood flow. Stiff arteries are characterized by increased PWV. Under these conditions, the reflected pulse wave increases the ventricular afterload and the ventricular systolic pressure, and thus puts a greater load on the heart (Figure). This process decreases diastolic pressure and jeopardizes coronary blood flow, which can eventually result in LVH, coronary ischemia, and heart failure. This helps explain why increased SBP heightens cardiovascular risk, particularly in elderly patients.
END-ORGAN MANIFESTATIONS OF UNCONTROLLED SYSTOLIC HYPERTENSION
The goal of therapy for hypertension is to reduce or prevent end-organ damage. The principal targets of hypertension include the heart, the cerebrovascular system, and the kidneys.
Cardiovascular disease. Coronary artery disease, heart failure, and LVH are often the result of long-standing hypertension. As discussed above, the vascular remodeling and arterial stiffness that occur with systolic hypertension lead to LVH, diastolic dysfunction and, eventually, diastolic heart failure. Diastolic heart failure is more prevalent than systolic heart failure among the elderly; its morbidity is comparable to that of systolic heart failure.12 Patients with diastolic heart failure are often diabetic or obese or have chronic renal disease.
1. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560-2572.
3. Franklin SS, Jacobs MJ, Wong ND. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001;37:869-874.
4. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-13.
5. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479-486.
6. Longini IM, Higgins MW, Hinton PC, et al. Environmental and genetic sources of familial aggregation of blood pressure in Tecumseh, Michigan. Am J Epidemiol. 1984;120:131-144.
7. Feinleib M, Garrison RJ, Fabsitz R, et al. The NHLBI twin study of cardiovascular disease risk factors: methodology and summary of results. Am J Epidemiol. 1977;106:284-285.
8. Biron P, Mongeau JG, Bertrand D. Familial aggregation of blood pressure in 558 adopted children. Can Med Assoc J. 1976;1115:773-774.
9. Oparil S, Zaman A, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003;139:761-776.
10. Fava C, Burri P, Almegren P, et al. Heritability of ambulatory and office blood pressure phenotypes in Swedish families. J Hypertens. 2004;22:1717-1721.
11. Palatini P, Julius S. Relevance of heart rate as a risk factor in hypertension. Curr Hypertens Rep. 1999;3:219-224.
12. Aurigemma GP, Gaasch WH. Diastolic heart failure. N Engl J Med. 2004;351:1097-1105.
13. World Health Organization. WHO World Health Report. Geneva: World Health Organization; 2002.
14. Lindholm LH, Ibsen H, Dahlšf B, et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
15. Shlipak MG, Heidenreich PA, Noguchi H, et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med. 2002;137:555-562.
16. Townsend RR. Cardiac mortality in chronic kidney disease: a clearer perspective. Ann Intern Med. 2002;137:615-616.
17. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med. 2002;137:563-570.
18. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-1225.
19. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336:1117-1124.
20. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344:3-10.
21. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the
PREMIER clinical trial. JAMA. 2003;289:2083-2093.
22. Elmer PJ, Obarzanek E, Vollmer WM, et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med. 2006;144:485-495.
23. Seppa K, Sillanaukee P. Binge drinking and ambulatory blood pressure. Hypertension. 1999;33:79-82.
24. Zilkens RR, Burke V, Hodgson JM, et al. Both red wine and beer elevated blood pressure in normotensive men. Hypertension. 2005;45:874-879.
25. Schillaci G, Pasqualini L, Vaudo G, et al. Effect of body weight changes on 24-hour blood pressure and left ventricular mass in hypertension: a 4-year follow-up. Am J Hypertens. 2003;16:634-639.
26. Aucott L, Pooblan A, Smith WCS, et al. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes. Hypertension. 2005;45:1035-1041.
27. Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized controlled trials. Ann Intern Med. 2002;136:493-503.
28. Ishikawa-Takata K, Ohta T, Tanaka H. How much exercise is required to reduce blood pressure in essential hypertensives: a dose-response study. Am J Hypertens. 2003;16:629-633.
29. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-2987.
30. Kuster GM, Kotlvar E, Rude MK, et al. Mineralocorticoid receptor inhibition ameliorates the transition of myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005;111:420-427.
31. Townsend RR, Holland OB. Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension. Arch Intern Med. 1990;150:1175-1183.
32. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA. 2001;286:1882-1885.
33. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-592.
34. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
35. Julius S, Nesbitt SD, Egan BM, et al; Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685-1697.
36. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;328:914-921.
37. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677-684,
38. Wang JG, Li Y, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers. A quantitative review. Hypertension. 2007;50:181-188.
39. Moser M, Setaro JF. Resistant or difficult-to-control hypertension. N Engl J Med. 2006;355:385-392.
40. Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens. 2004;22:863-869.
41. Clozel M, Breu V, Burri K, et al. Pathophysiologic role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993;365:759-761.
42. Krum H, Viskoper RJ, Lacourciere Y, et al. The effect of an endothelin receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med. 1998;338:784-791.
43. Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation. 2004;109:1186-1193.
44. Muller DN, Luft DC. Direct renin inhibitions with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol. 2006;1:221-228.
45. Benedict CR. Centrally acting antihypertensive drugs: re-emergence of sympathetic inhibition in the treatment of hypertension. Current Hypertension Reports. 1999;1:305-312.
46. Sanjuliani AF, de Abreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. International J Clin Practice. 2006;60:621-629.
47. Abellán J, Leal M, Hernández-Menárguez F, et al. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. Kidney Int Suppl. 2005;93:S20-S24.
48. Meredith PA, Reid JL. Efficacy and tolerability of long-term rilmenidine treatment in hypertensive diabetic patients. A retrospective analysis of a general practice study. Am J Cardiovasc Drugs. 2004;4:195-200.